

# Hep C NS3 (vY-20): sc-17527

## BACKGROUND

The Hep C (Hepatitis C) is a small, enveloped, single-stranded, positive sense RNA virus belonging to the family *Flaviviridae*. Transmission of the virus occurs when blood from an infected individual enters the body of an uninfected individual. Hep C primarily replicates within hepatocytes in the liver, and circulating Hep C particles bind to receptors on the surface and enter these cells. Hep C replicates quickly, producing approximately one trillion particles each day in infected individuals. Hep C RNA polymerase has no proofreading function, so the virus has an exceptionally high mutation rate which may help it elude the host's immune system. Hep C infection results in chronic infections, liver cirrhosis, and hepatocellular carcinoma in most people. Hep C NS3 (nonstructural protein 3) has both protease and helicase activity and is essential for Hep C replication and proliferation.

## REFERENCES

1. Watashi, K. and Shimotohno, K. 2003. The roles of hepatitis C virus proteins in a novel action mechanism of the HCV core protein on gene regulation by nuclear hormone receptors. *Cancer Sci.* 94: 937-943.
2. Umehara, T., et al. 2004. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3. *Nucleic Acids Symp. Ser.* 48: 195-196.
3. Acosta-Rivero, N., et al. 2004. Nucleic acid binding in *Pichia pastoris*. *Biochem. Biophys. Res. Commun.* 323: 926-931.
4. Sansonno, D., et al. 2004. Detection and quantitation of HCV core protein in single hepatocytes by means of laser capture microdissection and enzyme-linked immunosorbent assay. *J. Viral Hepat.* 11: 27-32.
5. Alisi, A., et al. 2005. Thr 446 phosphorylation of PKR by HCV core protein deregulates G<sub>2</sub>/M phase HCC cells. *J. Cell. Physiol.* 205: 25-31.
6. Carabaich, A., et al. 2005. Profiles of HCV core protein and viremia in chronic hepatitis C: possible protective role of core antigen in liver damage. *J. Med. Virol.* 76: 55-60.
7. Gu, J., et al. 2005. Morphological alteration and biological properties of hepatocytes not related to tumorigenesis following transfection with HCV core protein. *J. Viral Hepat.* 12: 20-26.
8. Kimball, P., et al. 2005. HCV core protein augments cyclosporine immunosuppression. *Transplant. Proc.* 37: 652-653.
9. Alvarez-Lajonchere, L., et al. 2006. Hepatitis C virus (HCV) core protein enhances the immunogenicity of a co-delivered DNA vaccine encoding HCV structural antigens in mice. *Biotechnol. Appl. Biochem.* 44: 9-17.

## SOURCE

Hep C NS3 (vY-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of Hep C NS3 origin.

## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-17527 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

## APPLICATIONS

Hep C NS3 (vY-20) is recommended for detection of NS3 region of Hep C origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Molecular Weight of Hep C NS3: 70 kDa.

## RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) or our catalog for detailed protocols and support products.



Try **Hep C NS3 (1828): sc-69938**, our highly recommended monoclonal alternative to Hep C NS3 (vY-20).